breastfeeding and tirzepatide While Breastfeeding: Safety & Guidelines Postpartum Support: Tirzepatide, Yerba Mate

Patients who continue GLP-1 therapy generally maintain more stable results, though the long-term effects of these medications are still being studied

Source: Eli Lilly press release, May 21, 2026

Clinical Contraindications Not appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN 2, or for patients who are pregnant or breastfeeding

According to clinical studies, the average weight loss was: Tirzepatide 5-mg doses Average change in weight was -15% Tirzepatide 10-mg dose Average change is weight was -19.5% Tirzepatide 15-mg dose Average change in weight was -20.59% Impressively, in large clinical trials there were also improvements in cardiometabolic measures